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Efficient integration of functional genes is an essential prerequisite
for successful gene delivery such as cell transfection, animal trans-
genesis, and gene therapy. Gene delivery strategies based on viral
vectors are currently the most efficient. However, limited cargo
capacity, host immune response, and the risk of insertional muta-
genesis are limiting factors and of concern. Recently, several groups
have used transposon-based approaches to deliver genes to a
variety of cells. ThepiggyBac (pB) transposase in particular has been
shown to be well suited for cell transfection and gene therapy
approaches because of its flexibility for molecular modification,
large cargo capacity, and high transposition activity. However,
safety considerations regarding transposase gene insertions into
host genomes have rarely been addressed. Here we report our
results on engineering helper-independent pB plasmids. The
single-plasmid gene delivery system carries both the piggyBac
transposase (pBt) expression cassette as well as the transposon
cargo flankedby terminal repeatelement sequences. Improvements
to the helper-independent structure were achieved by developing
new plasmids in which the pBt gene is rendered inactive after
excision of the transposon from the plasmid. As a consequence,
potentially negative effects that may develop by the persistence
of an active pBt gene posttransposition are eliminated. The results
presented herein demonstrate that our helper-independent
plasmids represent an important step in the development of safe
and efficient gene delivery methods that should prove valuable
in gene therapy and transgenic approaches.
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The ability to safely and efficiently integrate genes into a hostgenome is essential for successful genetic modification strate-
gies in the context of functional genomic studies, transgenesis, and
gene therapy. Currently, the most commonly used vectors for
permanent or transient transfer of genes in preclinical gene
therapy trials are virus-based; however, nonviral vectors are also
being developed. Whereas it is possible to achieve stable genomic
integration with high efficiency using viral vectors, multiple
studies have pointed out serious disadvantages. Adenoviruses,
for example, have been shown to evoke host immune responses
(1), whereas retroviruses preferentially integrate transgenes into
euchromatin thereby increasing the risk of insertional mutagen-
esis. Viral systems are also limited in cargo size (2, 3), restricting
the size and number of transgenes and their regulatory elements.
Finally, biosafety considerations and production costs are
additional factors to consider when using viral vectors (3, 4).
To avoid some of the potential drawbacks of viral systems,
transposons have been tested and successfully used as an alter-
native in a diverse field of applications. DNA transposons are
mobile elements that generally use a “cut and paste” mechanism
in which the DNA is excised by double strand cleavage from the
donor molecule and consecutive integration into the acceptor
molecule. Many of the initial experiments were conducted using
Sleeping Beauty (SB) (5). More recently however, pBt from the
moth Trichoplusia ni has been widely used as a means for gene
delivery in a variety of applications such as cell line transforma-
tion (6–9), mutational analysis (10), and gene therapy (11).
Additionally, the pB system displays several highly desirable
features that are of great advantage for transgene integration;
pBt is very efficient and has a higher transposition activity than
any of the Sleeping Beauty variants (9, 12, 13); the pB system
allows for remobilization of transposons as they can be removed
without leaving a “footprint” (14) and under certain conditions,
pBt does not show any overproduction inhibition as do some
members of the Tc1/mariner transposon superfamily (13, 15).
Finally pBt has been shown to deliver transposons up to 18 kb
(8), the largest cargo size described to date in any of the trans-
poson or integrating viral systems.
Most transposition attempts for cell line transfections or gene
therapy experiments with pB have used the two-plasmid donor-
helper system. The donor plasmid contains inverted terminal
repeats flanking the transgene while the helper plasmid transi-
ently expresses the pBt enzyme, which catalyzes the insertion
event from the donor plasmid to the host genome (16). Similarly,
two-component systems have been used for pBt-initiated trans-
genesis where a donor plasmid is coinjected with transposase
RNA (17, 18). However, this approach is problematic because
of issues with RNA stability. The two-plasmid approach works
well with cell line transfections but in our experience, this
approach did not support transgenesis using Intracytoplasmic
Sperm Injection (ICSI) (19).
To develop a pB system that is more suitable for transgenesis
and gene therapy experiments, helper-independent single plas-
mids were constructed, containing both the donor and helper ele-
ments of the pB transposition system in the same circular
construct, similar to plasmids previously described (20, 21). This
cis-acting plasmid configuration ensures that both components,
transposon, and transposase, are delivered simultaneously to
the nucleus and hence should result in an improved transposition
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efficiency. Here, we describe the structure and function of three
such plasmids (piGENIE, pmGENIE-2, and pmGENIE-3): The
plasmids were designed to contain the transposase in an arrange-
ment that prevents the activation of the enzyme in case of random,
nontranspositional integration of the plasmid backbone that ori-
ginates from the plasmid after transgene excision. Such a feature
will be invaluable in clinical relevant settings as it increases the
safety of plasmid-based research and gene therapy approaches
as it prevents some of the potential genotoxic effects intrinsic in
these systems.
Results
Helper-Independent Insect pB Vectors (piGENIE) are Active in HEK293T
Cells and Support Transgenesis. As a first step, a helper-indepen-
dent plasmid was constructed. This plasmid contained a CMV-
early-enhancer/chicken β-actin and β-globin intron (CAG)
promoter-driven insect pB transposase gene (ipBt), where both
the CAG promoter and the pBt gene are located on the back-
bone, outside the terminal repeat elements (TREs) of the trans-
poson (piGENIE). The transposon for piGENIE was engineered
to contain the enhanced green fluorescent protein gene as a
reporter, as well as a cassette with Hygromycin resistance and
Kanamycin resistance genes to facilitate selection in eukaryotes
and prokaryotes, respectively (Fig. 1A and Fig. S1).
To assess the transposition activity in human cells, embryonic
kidney cells (HEK293T) were transfected with 400 ng of
piGENIE plasmids. The plasmid was administered in a circular
form to cells by lipofection. To contrast the efficiency of
piGENIE-mediated transgene integration with nontransposi-
tional (i.e., endogenous) integration of the plasmid, cells were
also transfected with 400 ng of a construct lacking a functional
pBt gene (piGENIE∕ΔpiggyBac). Resistant clones larger than
1 mm were counted after 3 weeks of selection on Hygromycin
(Fig. 1B). These experiments demonstrated that piGENIE was
active in mammalian cells: 5.8% of all cells used for the
experiment displayed stable integration as exemplified by EGFP
expression and Hygromycin resistance. Furthermore, piGENIE
was able to mediate transposition at levels significantly above
those of random, nontranspositional integrations (Table S1).
Genomic DNA (gDNA) from two clones derived from two
individual, stably transfected single HEK293Tcells was analyzed
for the number of transgene integration sites by Southern blot
with a transposon-specific probe for EGFP. The gDNA was
digested with restriction enzymes ScaI and BamHI. Only ScaI
cuts once inside the transposon to leave a 4,447 bp fragment
containing the EGFP gene. BamHI is expected to cut human
gDNA about every 7,000 bp. Depending on genomic environ-
ment of the transposon insertion site, each of the individual
insertions facilitated by piGENIE resulted in an individual band
of at least 4,447 bp in Southern blots. At the used concentration,
piGENIE proved to be extremely competent as both clones
tested carried multiple transposons (Fig. 1C).
Only a few laboratories have employed transposases as a tool
for animal transgenesis (2, 17, 18, 22, 23). These experiments
have been based on supplying the transposase either as protein,
mRNA, or in the helper plasmid of the donor-helper system. To
avoid difficulties with proteins or mRNA and because, in our
hands, the helper-donor approach did not yield any transgenic
animals when employing ICSI, we examined whether piGENIE
could be used as an effective tool for transgenesis. ICSI transgen-
esis performed with the circular form of the plasmid and fresh
sperm resulted in high rates of transgenic animals. For example
using 0.663 pg of piGENIE resulted in 18 transgenic mice, repre-
senting 69.2% of all animals born and 22.8% of oocytes injected
(Table S2). Surprisingly, all of the transgenic animals exhibited
mosaic EGFP signals by epifluorescence (Fig. 1D). When F0
animals were mated to wild-type mates of the same strain, none
of the resulting transgenic F1 pups displayed mosaicism. All of
the F1 animals that survived to adulthood were sacrificed at
2 years of age and examination of their tissues showed no signs
of tumor formation. The phenomenon of mosaicism in F0 trans-
genic animals is thought to be due to transgene integration after
the first chromosomal replication. However, it is also possible
that nontranspositional integration of the plasmid as a whole
or of the backbone only (posttransposition) resulted in the inte-
gration of an active ipBt, which ultimately led to the observed
mosaicism. From cell transfection and transgenesis studies with
transposons, it is evident that, in virtually every instance reported,
there is some nontranspositional integration of plasmids (2, 5, 9,
13, 18, 24, 25). Such nontranspositional integrations were shown
to apply to both helper and donor plasmids (2). To distinguish
backbone insertions from whole plasmid insertions, several
PCR assays were performed on gDNA from 10 founder mice,
and the piGENIE plasmid as a control, priming for several sites
within the plasmid: (i) EGFP, (ii) ipBt, (iii) a region spanning the
30-end of the CAG promoter to ipBt, and finally (iv) a sequence
spanning ipBt to the 30-TRE (Fig. 1E). Whereas, as expected,
all of the mice were positive for EGFP, this analysis also yielded
amplification products in all of the samples for the ipBt gene
and the promoter, indicating nontranspositional insertion of
the plasmid. More specifically, as no amplicons were obtained
for the region spanning the ipBt gene and the 30-TRE, we
assumed that all of these observed nontranspositional insertions
were derived from backbone segments only. pBt has been shown
to excise transposons without leaving a footprint in the donor
genome (14). It is therefore probable that these nontransposi-
Fig. 1. piGENIE supports cell transfections and animal transgenesis. (A)
Schematic representation of piGENIE. The transposon cassette is delimited
by the 30- and 50-TREs. Transposon size, restriction sites within the transposon,
and Southern blot probe location are indicated. (B) 0.5 × 105 HEK293Tcells
were transfected with 400 ng of piGENIE plasmid. As control for random
nontranspositional integration of the plasmid HEK293Tcells were transfected
with 400ngof a construct (piGENIE∕ΔpiggyBac) lacking a functional pBt gene.
Transposition activity was measured by counting methylene blue stained,
hygromycin-resistant colonies after a three-week selection period. Data are
shownasmeanvalueswith SD (N ¼ 3). (C) Southernblot analysis of gDNAfrom
a clonal expansion of transfected cells to analyze insertion events. Samples
were digested with ScaI and BamHI and probed with a DIG-labeled DNA frag-
ment corresponding to the EGFP gene. (D) Depiction of mosaic piGENIE trans-
genicmice. (E) Assessment of plasmid backbone insertions into the genome of
ten piGENIE mice by PCR analysis (piGENIE plasmid served as a control). The
analysis revealed that whereas all animals are transgenic for EGFP (top panel),
they also displayed ipBt gene insertions (second panel from the top). More-
over, amplification products for the ipBt gene with its CAG promoter were
obtained (second panel from the bottom) but not from a region spanning
the ipBt gene and the 30-TRE (bottom panel), indicating nontranspositional
insertion of the plasmid backbone only but not of the entire plasmid.
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tionally inserted plasmid backbones originated from the recircu-
larized plasmid after excision of the transposon and its TREs as
previously reported (9). Because insertion of an active pBt with
its promoter into the genome of a host may result in hopping of
the transgene—a feature advantageous for gene function studies,
but undesirable for gene therapy or transgenesis experiments—a
unique plasmid was engineered to ameliorate this issue.
pmGENIE-2: A Mouse Codon-Biased Self- Inactivating Vector.
pmGENIE-2 contained the same transposon as piGENIE, but
differed from it in two components: (i) a mouse-codon-optimized
pBt gene proven more effective in cell transfection experiments
(26) replaced the ipBt gene, and (ii) the 30-TRE was located be-
tween the CAG promoter and pBt gene (Fig. 2A and Fig. S1).
Therefore, enzymatic excision of the transposon from the plasmid
during transposition would result in the separation of the CAG
promoter from the mpBt gene. The promoterless mpBt gene, re-
siding in the remaining plasmid backbone should therefore be in-
active if inserted nontranspositionally into the genome of the host
by the DNA repair mechanism, reducing the possibility of poten-
tial genotoxic effects.
HEK293T cells were transfected with 400 ng of circular
pmGENIE-2 plasmid or the respective control (pmGENIE-2∕
ΔpiggyBac). To compare our helper-independent system to the
more commonly used two-component donor-helper system
(Fig. S1), HEK293T cells were also transfected with 100 ng of
helper plasmid containing the mpBt gene driven by the CAG
promoter (pCX-mpB) and 200 ng of donor plasmid carrying
the EGFP, Hygromycin resistance, and Kanamycin resistance
genes. Cells were maintained under Hygromycin selection for
3 weeks to exclude the possibility of detecting persistent episomal
plasmid. To validate our approach of inactivating nontransposi-
tionally inserted pBt genes, several PCR screens were performed.
Genomic DNA, extracted from mixed populations of HEK293T
cells transfected with pmGENIE-2 were used for these reactions.
For comparison, gDNA frompiGENIE transfected cells was used.
The respective plasmids (piGENIE and pmGENIE-2) served as
positive controls for successful amplification. The obtained ampli-
cons were subsequently analyzed by sequencing. Amplification of
a region spanning the 30-end of the CAG promoter and the ipBt
gene resulted in products from the gDNA as well as the piGENIE
plasmid control [Fig. 2B (i)] indicating some nontranspositional
insertion of the piGENIE plasmid backbone as also demonstrated
in Fig. 1E. Long-range PCR using primers that anneal within the
mpBt gene and downstream of the 50-TRE result in 11.2 kb
products from the pmGENIE-2 plasmid only but not from the
gDNA of pmGENIE-2 transfected cells [Fig. 2B (ii)], verifying
the absence of persistent episomal plasmids in the sample. It
further suggests the lack of nontranspositional insertion of full-
length plasmid. In contrast, the same amplification reaction gave
rise to a 1.0 kb PCR product from gDNA, an amplicon absent in
the plasmid control reaction (Fig. 2B (iii)], representing amplifi-
cation from the promoterless backbone that remains after trans-
poson excision. Taken together, these findings validate our
strategy of inactivating mpBt in pmGENIE-2 by separating the
gene from its promoter during transposition. Thus, nontransposi-
tional insertion of the plasmid backbone can result only in the
incorporation of a promoterless transposase gene. The impor-
tance of this feature of pmGENIE-2 is further emphasized by
the detection of PCRamplicons for pBt fromnontranspositionally
inserted helper plasmid in donor-helper experiments (Fig. S2).
As a next step, pmGENIE-2 was evaluated in regards to its
transposition activity. Colony-forming assays showed that the
donor-helper system, which demonstrated efficiencies similar
to those of previous experiments (9), resulted in half as many
stably transfected colonies when compared to the helper-inde-
pendent approach (Fig. 2C). Furthermore, pmGENIE-2 was able
to mediate transfection rates at levels considerably above those
resulting from piGENIE-mediated integration (Table S1).
To assess the influence of plasmid concentration on the
number of simultaneous transgene integrations, HEK 293T cells
were transfected with different concentrations of pmGENIE-2
(Fig. 2D). Genomic DNA was extracted from clonal expansions
of single transfected HEK293T cells after they had reached
confluence in a T75 flask at approximately four months. Southern
blot analysis of this gDNA revealed that lower plasmid amounts
result in fewer transgene insertions, with the highest number of
insertions at 400 ng. These preliminary data suggest that
pmGENIE-2, in the highest amount tested, is a powerful tool
for in vitro transposition and may be better for applications, such
as mutagenesis, where large numbers of inserts are desirable.
Fig. 2. Analysis of pmGENIE-2. (A) Schematic representation of pmGENIE-2.
The transposon cassette is delimited by the 30- and 50-TREs. Transposon size,
restriction sites within the transposon, and Southern blot probe location
are indicated. (B) ThempBt is separated from its CAG promoter during trans-
position: 0.5 × 105 HEK293Tcells were transfected with 400 ng of pmGENIE-2
plasmid. As a control, HEK293T cells were transfected with 400 ng
pmGENIE-2∕ΔpiggyBac lacking a functional pBt gene. Genomic DNA,
extracted from a mixed population of HEK293T cells transfected with
piGENIE or pmGENIE-2 were used for PCR analysis, where piGENIE or
pmGENIE-2 plasmid DNA served as control. (i) Amplification of a region span-
ning the 30-end of the CAG promoter and the ipB gene resulted (schematic
depiction of primers are indicated as arrows) in products from the gDNA
and from the piGENIE plasmid control. (ii) Long-range PCR of the complete
transposon, priming within thempBt gene and downstream of the 50′-TRE re-
sulted in full-length 11.2 kb products from the pmGENIE-2 plasmid control but
not from the gDNA of pmGENIE-2 transfected cells. (iii) In contrast, the same
amplification reaction gave rise to a smaller 1.0 kb amplicon from gDNA, but
not from the plasmid. (C) Transposition activities of pmGENIE-2 (400 ng) and
the helper-donor (200 ng donor and 100 ng helper) plasmids (and equal
amounts of their respective controls) as measured by counting hygromycin-
resistant colonies. Data are shown as mean values with SD (N ¼ 3). (D) Repre-
sentative samples of a Southernblot analysis ofHEK293Tcells transfectedwith
different amounts of pmGENIE-2 (E) Depiction of full transgenic, mosaic and
nontransgenic pmGENIE-2 transgenic littermates. (F) Southern blot analysis of
gDNA from pmGENIE-2 transgenic founder and F1 mice.
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Subsequently, ICSIwas performed to investigate pmGENIE-2’s
ability to support animal transgenesis, using the sameexperimental
setup as described for piGENIE. Visual assessment of the animals
by epifluorescence revealed that pmGENIE-2 is indeed amenable
to in vivo experiments and, contrary to piGENIE, results in both
mosaic and full transgenic animals (Fig. 2EandTableS2). Similarly
to piGENIE ICSI experiments, all transgenic F1 animals obtained
from mating F0 to wild-type animals were true transgenics and
survived to 2 years of age without any detectable tumorigenesis.
To assess transposon integration frequency for these transgen-
esis experiments, gDNAobtained from five foundermice (F0) was
analyzed by Southern blots with anEGFP-specific probe.All of the
mice displayed only a few transgene insertions, with one mouse
having seven insertions whereas two other founders only showed
the presence of one transgene (Fig. 2F). In comparison to cell
transfections, it appears that pmGENIE-2 is less efficient in insert-
ing transposons into oocytes. However, the significant differences
in the two experimental systems do not allow for such a conclusion.
Transgenic founders (F0) werematedwithwild-type B6D2F1mice
to evaluate transposon transmission through the germline, again
by subjecting gDNA from these F1 animals to Southern blot
analysis. Two animals (F1-6 and F1-8) inherited one out of two
transgenes, whereas the other animals inherited all copies present
in the respective founders.Moreover, a comparison of the banding
patterns for F0 and F1 animals indicated that the transgenes were
not subject to relocation by local hopping, demonstrating the
validity of our approach for inactivating the transposase gene.
The Southern blot analyses for both pmGENIE-2 HEK293T
cell transfection and ICSI-mediated mouse transgenesis indicated
the presence of bands smaller than 5 kb. However,HindIII restric-
tiondigestion of the gDNAused in these experiments should result
in fragments of at least 5004 bp or larger (Fig. 2 and Fig. S1).
We assumed that these bands originate from nontranspositional
insertions of plasmid fragments that contain the EGFP transgene.
Genomic location of transposon integrations were then
characterized in several individual HEK293Tclones and F1 trans-
genic mice by either inverse or vectorette PCR. A summary of the
identified insertion sites are listed in Table S3. Our results were
similar to other studies describing insertion patterns for pBt
(12, 27). Approximately half of the cell line integrations were
found in intergenic regions. However, we also identified three in-
tronic locations and one insertion into an exon of the cadherin-10
gene. In contrary, all of the transposon-gDNA junctions in the
transgenic animals could be assigned to intergenic regions. While
it is possible that pBt displays specific integration patterns depend-
ing on cell type, species, or experimental setup, the limited number
of integration sites analyzed precludes such a conclusion.
Additional evidence for the functional competence of the
plasmid was obtained by antibody studies with oocytes injected
with pmGENIE-2. The time course demonstrated pBt expression
as early as 6 hours after sperm injection with peak production
at 30 hours (Fig. 3). At this time point the transgenic embryos were
at the two-cell stage and showed early EGFP expression, as
previously reported (21). At 48 hours, the embryos were at the
four-cell stage: the signal for the pBt decreased, presumably
because of inactivation of the pBt gene during transposition.
EGFP expression however, remained constant because of inser-
tion of the transposon into the oocyte genome.
pmGENIE-3: A Helper-Independent piggyBac Plasmid Optimized For
Gene Therapy Experiments. During pmGENIE-2 mediated trans-
position the CAG promoter and pBt are separated, rendering
the transposase inactive. Moreover, should pBt be inserted into
the genome by nontranspositional integration of the backbone,
it would remain inactive unless the activity of a promoter adjacent
to the site of insertion would drive its transcription in the correct
orientation. However, as the CAG promoter is part of the in-
serted transposon, it is possible that it could potentially influence
the transcription of genes downstream of the insertion site.
In the pmGENIE-3, the 30-TREof the transposon resideswithin
an intron engineered into the pBt gene near its 50-end (Fig. 4A and
Fig. S1). Such a design allows transcription of pBt only from
pretransposition plasmids but not from recircularized plasmid
backbones that remain after the transposition event. During trans-
position, pBt binds to the 30-TRE inside the chimeric intron as well
as to the 50-TRE, forming the synaptic complex. Hence, only a
truncated, inactive pBt gene would remain on the plasmid back-
bone after excision. This truncated pBt cannot contribute to any
hopping of inserted transposons, even if integrated into the host
genome by nontranspositional insertion and driven by a promoter
from an adjoining gene. Additionally, the CAG promoter left in
the transposon cannot contribute to aberrant gene activation,
as the small 50-end fragment of the pBt gene and the remaining
intron terminate at a stop codon (UAA) engineered into the
construct. This design should, in effect, mitigate any influence
on downstream host DNA genes.
As a first step, we evaluated the presence of an integrated pBt
backbone by genomic PCRof pmGENIE-3 transfectedHEK293T
cells following methods described for piGENIE transfections.
Sequence analysis of the obtained amplicon indicated that the
insertions derived from recircularized pmGENIE-3 plasmids, as
they contained reconstituted TTAA sites generated by transposon
excision and consecutive recircularization of the backbone plas-
mid. The data also confirmed that nontranspositional insertion
of the pmGENIE-3 backbone leaves only an inactive pBt behind
(Fig. 4A and Fig. S3). Again, we found no evidence of full-length
pmGENIE-3, indicating the absence of episomal pretransposi-
tional plasmid. More importantly, the data also indicates the lack
of nontranspositional insertion of full-length plasmid.
We investigated if the design of the plasmid would negatively
influence its transposition efficiency in in vitro and mouse trans-
genesis experiments. Our results from the colony-forming assay
demonstrated that pmGENIE-3 displayed the highest gene-deliv-
Fig. 3. Time course of piggyBac and EGFP protein expression in transgenic
embryos generated by ICSI. pBt expression was visualized by immunofluor-
escence using a polyclonal antibody for the pBt protein and is detectable
above background levels as early as 6 hours. Peak expression was observed
at about 30 hours corresponding with early detection of EGFP transgene
expression. Pictures in the Tm column represent transmission images of
the developing embryos. DAPI was used to visualize nuclei.
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ery efficiency as compared to the less intricate piGENIE and
pmGENIE-2 plasmids (Fig. 4B, Fig. S4, andTable S1). ASouthern
blot analysis of HEK293Tclones derived from transfected, single
HEK293Tcells showed a similar number of transgene insertions as
observed for the other two plasmids, indicating that pmGENIE-3
retained transposition competence (Fig. 4C). Insertion site data
obtained for pmGENIE-3 provided evidence that the modified
pBt gene retains its enzymatic transposition activity (Table S3).
ICSI transgenesis experiments were performed to assess the
potential of pmGENIE-3 as a tool for generating transgenic ani-
mals. At the most efficient concentration of circular pmGENIE-3,
11 transgenic mice were obtained, five of which were true trans-
genics (Table S2). Similarly to piGENIE and pmGENIE-2 ICSI
experiments, all pmGENIE-3 transgenic F1 animals obtained by
mating the F0 animals to wild-type mates were full transgenics
and are surviving to date without any detectable tumorigenesis.
Discussion
In this study, we developed unique helper-independent piggyBac
gene delivery plasmids. These plasmids are more effective for
HEK293T cell transfections and ICSI transgenesis than the two-
plasmid donor-helper approach. In piGENIE mediated transgen-
esis, all of the transgenic animals were mosaic. A PCR analysis of
gDNA from piGENIE mice revealed random, nontranspositional
insertion of the plasmid backbone, presumably in the linearized
form. pBt-mediated transposition from chromosomal DNA does
not alter the donor site but instead reconstitutes the original
TTAA tetranucleotide after excision of the transposon (14).
In plasmids, reconstitution of the TTAA site posttransposition
should result in the recircularization of the remaining linear back-
bones. Similar recircularization mechanisms have been described
in systems other than pB (28, 29). Recircularized plasmids remain
in the nucleus and are thought to be degraded over time.However,
our data suggests that some of these plasmids are inserted into the
host genome, possibly by the host DNA repair mechanism, as re-
ported elsewhere (30). As the piGENIE plasmid backbone con-
tains an active piggyBac gene, such insertions may result in pBt
transcription in the host cell and can thus cause transgene reloca-
tion. This may contribute to the observed transgenic mosaicism
and potentially to deleterious genotoxic modifications, resulting
in decreased fitness of the organism.
As an alternative approach, transpositions can be catalyzed by
supplying the transposase as mRNA (17). Instability of mRNA
restricts its duration of activity and therefore the risk of introdu-
cing genotoxic effects. However, it is possible for the mRNA to
undergo reverse transcription, potentially resulting in insertion of
the pBt cDNA into the host genome by nonhomologous recom-
bination (31). We modified our helper-independent piGENIE
plasmid in two steps, thereby significantly improving its safety.
The latest plasmid, pmGENIE-3 features an intron spanning
the 30-TRE that allows the transposase to be transcribed from
unmodified plasmids only. After transposition, the remaining
recircularized plasmid backbone contains a truncated transpo-
sase gene. Even if the recircularized plasmid is then integrated
into the host genome near an active promoter, the nonfunctional
pBt gene cannot be expressed due to lack of an initiation codon.
Additionally, after transposition, the pmGENIE-3 transposon
retains the CAG promoter, which now can only drive the expres-
sion of a nonfunctional short transcript with a preengineered stop
codon. As a consequence, the transposed promoter cannot
activate neighboring host genes upon integration. These safety
features integrated into pmGENIE-3 are of great importance
for any gene therapy approach using transposase-based systems,
as we and others (2, 5, 9, 13, 18) have reported a certain amount
of nontranspositional plasmid integration when using piggyBac-
or Sleeping Beauty-based transposition, independent of the speci-
fic system or application. The lack of full-length GENIE plasmid
insertions in all of our transfection experiments, further empha-
sizes the importance of self-inactivating plasmids for gene
delivery experiments.
To further reduce the risk of unwanted, potentially oncogenic
modifications of the host genome, additional elements can be
integrated into the vector design. For example, the use of a
chimeric transposase consisting of the transposase itself and a
DNA binding domain such as zinc finger motifs, could potentially
target the transposon integration to specificDNAregions. pBtwas
previously shown to be amenable to such molecular modification
while retaining its full transpositional activity, whereas other trans-
posases lost their activity (9, 32). Furthermore, Chen et al. (33)
reported using plasmids modified to carry chicken-beta-globin
insulators flanking the transgene in their pBt-mediated transposi-
tion system in human embryonic stem cells. These insulators have
the potential not only to shield transcribed regions of the host
genome from outside regulatory influences but also to act as
barriers against position-dependent transgene silencing.
In our initial experiments with HEK293T cell transfection, a
large number of transposition events per transfection were
observed at the highest plasmid concentration. This result suggests
that our CAG promoter-driven pmGENIE plasmid is a powerful
tool for in vitro transposition. However, it may be better suited for
mutagenesis experiments or other applications where large num-
bers of inserts are desirable. For example, a high number of trans-
gene insertions may be of advantage during tumor reduction
approaches where plasmids are used to introduce suicide genes.
Here, multiple insertions of transgenes can potentially amplify
the toxic effect by increasing expression of the suicide gene. Trans-
fections with lower amounts of plasmids yielded cells with fewer
transgene integrations. Hence, for transfection experiments
requiring fewer inserts, using lower plasmid concentrations, or
modifying the plasmids to contain a less potent pBt promoter
may prove beneficial.
Southern blots analyses of gDNA from transgenic animals did
not indicate any concatemerized insertion of the transgenes. Such
concatemerized insertions are commonly reported for transgen-
esis performed with pronuclear microinjections and ICSI. This
Fig. 4. Analysis of pmGENIE-3 transposition. (A) Schematic representation of
pmGENIE-3 and the truncation of the pBt gene during transposition. The
transposon cassette forgenomic integration is delimitedby the30- and50-TREs.
Ci represents the chimeric intron. Transposon size, restriction sites within
the transposon, and Southern blot probe location are indicated. (B)
0.5 × 105 HEK293Tcells were transfected with 400 ng of pmGENIE-3 or
pmGENIE-3∕ΔpiggyBac. Transposition activity was measured by counting
methylene blue stained, hygromycin-resistant colonies after a 3 week
selection period. Data are shown as mean values with SD (N ¼ 3).
(C) Southern blot analysis of HindIII digested gDNA from clonal expansions
of pmGENIE-3 transfected cells. Samples were probed with a DIG-labeled
DNA fragment corresponding to the EGFP gene. (D) Southern blot analysis
of HindIII digested gDNA from pmGENIE-3 transgenic mice.
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phenomenon is believed to be due to ligation of the linear trans-
genes in a head to tail orientation and subsequent integration into
the host genome by homologous recombination (2, 30, 34–36).
Transgene insertions mediated by the pBt seem to avoid such
concatemers. During pB transposition a single transposon is
excised from the plasmid to form a synaptic complex that appears
to prevent the ligation of the transgenes into concatemers. There-
fore, the cut and paste mechanism of transposases appears to
ensure that only individual transgenes excised from the plasmid
participate in transposition.
We have noted nontranspositional insertions of single plasmid
constructs as well as donor and helper plasmids during our trans-
fection and transgenesis experiments. These observations are
shared by many others (2, 5, 9, 13, 18, 24, 25); however, there
are reports demonstrating a complete removal of the plasmids
by degradation, posttransposition (37). We are presently unable
to consolidate these contradictory findings; however, it is possible
that the extend of this random, nontranspositional insertion of
plasmids is cell and tissue specific or dependent on plasmid
architecture and methods used in plasmid preparation. In in vitro
experiments, multitransgene insertion or local hopping of the
transposon may be a lesser concern. Here, such events may
potentially be genotoxic, but can result only in an increased num-
ber of dead cells, thereby reducing transfection efficiencies. In
gene therapy approaches, avoiding deleterious events introduced
by the plasmid or plasmid fragments is critical. Therefore, the
safety features incorporated into pmGENIE-3 represent an
important step toward using transposon-based systems for gene
therapy where reporter genes will be replaced by therapeutic
genes. The architecture described herein should also be applicable
to transposase systems such as Sleeping Beauty or Tol2,
improving their safety in gene therapy experiments.
Materials and Methods.
Here, we provide a brief summary of the applied methods. Please see SI Text
for a detailed description.
Plasmid Development. The piGENIE and pmGENIE plasmids by basic molecular
biology methods as described previously (9). The GATEWAY recombineering
method of Invitrogen was employed for the construction of the final
transposon bearing pGENIE plasmids by the use of LR Clonase enzyme.
Cell Transfections. Cell culture and transfections were performed as pre-
viously (9).
Southern Blot Analysis. Southern blot analysis was performed as described
previously (22).
Transposon Insertion Sites. Insertion sites were analyzed, either by Vectorette
(Sigma) or inverse PCR.
Detection of NonEnzymatic Plasmid Insertion. PCR was performed to analyze
nontranspositional insertion.
Immunohistochemistry. After fixation and removal of the zona pelucida,
oocytes were incubated with primary piggyBac antibody followed by
secondary antibody staining.
Transgenesis. The procedures were performed as previously described with
only minor modifications (19).
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